Atisama Therapeutics

Atisama Therapeutics is a pre-clinical stage biotechnology company focused on developing selective inhibitors of the NF-kB signaling pathway to treat chronic inflammatory and autoimmune diseases. The company's technology is based on small molecule mimetics of the NEMO-binding domain (NBD) peptide, which prevents the assembly of the IKK complex. This targeted approach allows for the inhibition of inflammatory signaling while maintaining the essential basal activity of NF-kB, potentially avoiding the toxicity seen with previous broad-spectrum inhibitors. A spin-out from Columbia University, Atisama is leveraging decades of research into NF-kB biology to advance its pipeline toward clinical trials. The company's lead programs are currently focused on indications such as inflammatory bowel disease and rheumatoid arthritis.